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Depakine or dipropyl-Na-acetate (DPA), generic term sodium valproate was 
first synthesized by B . S. Burton in 1981 (cited after 8). G . Carraz et al . (1964) 
propose the first clinical trial of its anticonvulsive effect. I t causes pharrnacody-
namically an increase of G A B A brain tissue concentration by suppressing of its 
physiological dissociation (7, 8). 
Dipropyl acetate (DPA) (trivial term depakine) produced in 1966 by the 
French laboratory "Labase" was placed at our disposal in the Clinic of neurology, 
Higher Institute of Medicine, Varna, to be tested in clinical conditions. The main 
objective of the clinical experiment was to influence on the frequency of epilep-
fits and E E G changes in childhood depending on duration of treatment (between 
month and 4 years long). 
Some patients aged between one year and a half and 14 years with insuffi-
iently influenced and even untreated forms of epilepsy were selectively covered 
by our study. This series included 50 children (26 girls and 24 boys). On table 1 
е can see patients' age, the onset of epileptic fits and of depakine therapy. 
T a b l e 1 
Age in years 
Patients* number depending on : 







(6 % ) 
(32 % ) 
(18 % ) 
(10 % ) 
(30 % ) 






(4 % ) 
( И % ) 
(22 % ) 
(40 % ) 
(20 % ) 
о t a 1 50 (100 % ) 50 (100 % ) 
The dosage of depakine was at the average 30 rng/kg b. w. divided into 2 t i l l 
times daily. The efficacy of action was clinically estimated according to the 
schema: a) very good effect — 75 up to 100 per cent; b) a middle one — 74 to 
50 per cent, and c) below 50 per cent becoming less frequent of epileptic fits — a 
poor effect. We objectified the therapeutic effect by using an E E G method. We 
performed background registrations with all the patients during treatment as 
well as after finishing the clinical trial. Standard functional loading and medica-
mentous sleep were applied during E E G registrations. The results obtained were 
processed according to the methods of variational and correlational analysis. 
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Results and discussion 
Focal neurologic signs became apparent in 12 patients. The rest ones did not 
demonstrate any significant abnormalities of the neurologic state. Concerning 
the etiology it has to be noted that it was not clarified in 20 patients. The following 
main reasons were revealed in the rest 30 patients: perinatal brain damage (8 ca-
ses), postnatal labour injury (12 ones), meningoencephalitis (6 ones), and surviv-
ed intoxication (4 ones). The frequency of epileptic fits varied between 1—5 
daily (in 33 cases), 6—7 fits weekly (in 11 cases), and 1—4 fits monthly (in 6 pa-
tients). The structure of nosologic characteristics of different epileptic fits and 
their influencing by depakine is presented on table 2. 
T a b l e 2 
Epilepsy form 100-75 % 7 4 - 5 0 % 4 9 - 0 % Total 
Grand mal 8 12 3 23 
Grand mal and petit 
mal 1 3 0 4 
Psychomotor epilepsy 4 2 1 7 
Small myotonic fits 4 2 3 9 
Small akinetic fits 1 3 3 . 7 
T o t a l 18 ( 3 6 % ) 22 (44 % ) 10 ( 2 0 % ) 50 (100 % ) 
Our data showed that the preparation had a moderate therapeutic effect in 
cases of long-lasting drug application (at the average between 3 months and 3 
years) and depending on the form of epilepsy and its etiology. 
The therapeutic effect was confirmed by E E G control in all the patients. 
The severity of both local and general-brain epileptic bioelectrical changes was 
compared with the frequency and clinical results of different clinical forms. Un-
der the influence of depakine, there was a insignificant diminishing of the fre-
quency of convulsions (p<0,01) when generalized epileptic changes or slow-wave 
focuses were electroencephalographically registered. However, the detection of 
spontaneous irritative E E G focuses of sharp waves, complexes of peaks and slow-
waves was always supported by a decrease of epileptic manifestations in depakine 
treated patients (p<0,05). Best clinical pesults on E E G registrations were rela'-
ted to the reduction of generalized peaks — slow-waves provoked by hyperpnea 
and medicamentous sleep. The correlation between E E G and clinical picture in 
children without any generalization of bioelectric changes before depakine treat-
ment was statistically significant (p<0,01). These cl inico-EEG correlations sup-
port the moderateness of therapeutic influence of single depakine application (r-
=0,53) as it can be seen on table 3. 
I t has to be noted that 10 patients without any therapeutic effect of depakine 
were additionally given phenobarbital (6 cases), diphenylhidantoine (2 ones) and 
stasepine (2 ones). No side effects and unendurability to the drug were observed. 
The clinical influence of depakine was especially favourable concerning the 
treatment of grand mal, combined grand mal and petit mal with unclear etiology 
which showed on E E G some frequent discharges of sharp-slow waves spontaneous 
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T a b l e 3 
E C G changes 
Reduction of fit frequency 
100-75 % 7 4 - 5 0 % 4 9 - 0 % Total 
Generalized changes of 
sharp and peak waves 11 4 1 16 
Slow-wave focuses 0 I 2 3 Focuses of sharp peak waves 6 3 2 11 
Discharges of sharp-slow 
wave, both spontaneous and 
provoked by hyperventilation 7 1 4 12 
During medicamentous sleep 10 4 4 18 
Absence of response changes 
in functional tests 1 2 3 6 
T o t a l 35 15 16 66 
even provoked by functional loading. These data confirm the reports in the 
literature available (1 , 2, 4, 5) but do not agree with the investigations of other 
authors (3, 6) according to which grand mal was activated by depakine during 
medicamentous sleep. The preparation had a considerably better effect in patients 
without any organic neurologic signs and paroxysms or slow-wave focuses on E E G 
registration. There was a relatively good influence in cases of psychomotor epi­
lepsy, complicated absences, myoclonic-atactic forms, etc. with already proved 
brain damage. This treatment was, therefore, complex by using luminal, stase-
ine, diphenylhidantoine. Our results are in agreement with those of a number 
authors (1 , 2, 3, 8). 
Our experience shows that depakine at dosage of 20—40 mg/kg b. w. daily 
for a period of 3 months t i l l 3 years presents an anticonvulsive drug of choice which 
could be applied in clinical practice either alone or in combination with other 
anticonvulsants. I t is especially indicated in cases of generalized tonic-clonic 
convulsions, of absences and of focal epilepsy with more simple symptomatology. 
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ЛЕЧЕНИЕ ЭПИЛЕПСИИ В ДЕТСКОМ ВОЗРАСТЕ ДЕПАКИНОМ 
Р. Койнов, Д. Минчев, В. Христов 
Р Е З Ю М Е 
Авторы изучают эффект французского препарата Депакин при лечении пятидесяти 
детей, больных эпилепсией в различной форме и резистентных к предшествовавшему лече­
нию другими медикаментами. Авторами принята оптимальная средняя дневная доза препа­
рата — 30мг/кг , принимаемая в два или три приема. Наблюдения показывают, что депакин 
может применяться с хорошим эффектом при генерализированных тоническо-клонических 
судорогах, очаговой эпилепсии и сложных абсансах с миоклоническими, астатическими и 
другими проявлениями ЭЭГ картины без грубых генерализированных изменений и очагов 
медленноволнового характера. 
Результаты наблюдений позволяют сделать вывод, что препарат, применяемый само­
стоятельно или в комбинации с другими антиконвульсивными медикаментами, является 
эффективным средством лечения эпилепсии в детском возрасте. 
